title: Red blood cell density distribution in uremic patients on acetate and bicarbonate hemodialysis.
abstract: Renal anemia is the result of reduced erythropoietin (EPO) biosynthesis in the diseased kidney and also in part the result of a reduced life span of red blood cells (RBCs). An increase in density and a decrease in enzyme equipment (aspartate aminotransferase; GOT) of RBCs reflect cell age. In the following study, the density distribution (median density D50; determined by Percoll density gradients) and GOT activities of RBCs were measured in patients on acetate (HDA; n = 15) and bicarbonate (HDB; n = 51) hemodialysis. Hemoglobin (Hb) concentrations were: in the HDB group, 9.1 +/- 3.4 g/dl; in the HDA group, 6.2 +/- 1.2 g/dl, and, in a control (C) group of healthy persons, 14.0 +/- 1.5 g/dl. 14 HDB patients with severe anemia received EPO therapy during 1 year. D50 were found as follows: group C, 1.0674 +/- 0.0016 g/ml; HDB, 1.0674 +/- 0.0015 g/ml, and HDA, 1.0660 +/- 0.0012 g/ml (HDA vs. group C: p less than 0.05; HDA vs. HDB: p less than 0.05. D50 were elevated in the subgroups of HDA and HDB patients with severe anemia (Hb less than 8 g/dl). During activated erythropoiesis by EPO therapy, D50 decreased from 1.06739 +/- 0.0015 to 1.0656 +/- 0.0014 g/ml. The GOT activities in RBCs demonstrated a rejuvenation of the RBC population in the HDB group (6.4 +/- 2.5 U/g Hb) and HDA group (5.9 +/- 3.1 U/g Hb) compared to group C (3.9 +/- 1.3 U/g Hb).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Klinikum Rudolf Virchow, Freie Universität Berlin, FRG.
authors.forename: H
authors.initials: H
authors.lastname: Hampl
authors.forename: E
authors.initials: E
authors.lastname: Riedel
authors.forename: G
authors.initials: G
authors.lastname: Wendel
authors.forename: P
authors.initials: P
authors.lastname: Scigalla
mesh_terms: D000085:Acetates; D019342:Acetic Acid; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001219:Aspartate Aminotransferases / Q000097:blood; D001639:Bicarbonates; D004905:Erythrocyte Aging / Q000187:drug effects*; D004906:Erythrocyte Count / Q000187:drug effects; D004912:Erythrocytes / Q000201:enzymology; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D015312:Hemodialysis Solutions; D006801:Humans; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis / Q000379:methods*; D012720:Severity of Illness Index; D012964:Sodium; D017693:Sodium Bicarbonate; D014511:Uremia / Q000097:blood* / Q000628:therapy
chemical_list: D000085:Acetates; D001639:Bicarbonates; D015312:Hemodialysis Solutions; D011994:Recombinant Proteins; D004921:Erythropoietin; D017693:Sodium Bicarbonate; D012964:Sodium; D001219:Aspartate Aminotransferases; D019342:Acetic Acid